You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Coronary artery calcification and cardiovascular disease in children with chronic kidney disease

Paoli, Saraa; Mitsnefes, Mark M.b

Current Opinion in Pediatrics:
doi: 10.1097/MOP.0000000000000059
NEPHROLOGY: Edited by Michel Baum
Abstract

Purpose of review: Cardiovascular disease is the leading cause of death in children and young adults with end-stage renal disease (ESRD). As adults, children with advanced chronic kidney disease (CKD) have extremely high prevalence of traditional and uremia-related cardiovascular risk factors. Coronary artery calcification is one of the earliest cardiovascular markers detected in children with ESRD. The purpose of this review is to examine the new developments in pathogenesis of coronary artery calcification and to describe recently published studies on this topic in children with CKD.

Recent findings: There is growing evidence that fibroblast growth factor 23 (FGF23) and Klotho factor play a key role in the development of coronary artery calcification in ESRD. Recent studies have shown that induction of vascular calcification begins in early normophosphatemic CKD by the reduction of vascular Klotho and increased FGF23 secretion. Pediatric studies confirmed the presence of abnormal FGF23 and Klotho metabolism and the association of increased circulating FGF23 with coronary artery calcification in children with CKD.

Summary: New developments in our understanding of the mechanisms of vascular calcification in patients with early CKD require further investigation of whether control of FGF23/Klotho metabolism will prevent or delay the development of coronary artery calcification and other cardiovascular outcomes.

Author Information

aDepartment of Pediatrics, University ‘SAPIENZA’, Pediatric Nephrology Policlinico Umberto I, Rome, Italy

bDivision of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

Correspondence to Mark M. Mitsnefes, MD, MS, Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC 7022, Cincinnati, Ohio 45229, USA. Tel: +1 513 636 4531; fax: +1 513 636 7407; e-mail: mark.mitsnefes@cchmc.org

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins